

Amendments to the Specification:

Please replace the first two full paragraphs on page 8 of the SUBSTITUTE SPECIFICATION filed on October 29, 2008 with the following amended paragraphs:

Fig. 1 is a graph showing the changes of intraocular pressure with time in respective administration groups. The intraocular pressure is expressed as a change from an initial intraocular pressure. □ represents a Compound A ((R)-(+)-N-(1H-pyrrolo[2,3-b]pyridine-4-yl)-4-(1-aminoethyl)-benzamide dihydrochloride) and isopropyl unoprostone combination administration group, ■ represents a single administration group of Compound A, [□] Δ represents a single administration group of isopropyl unoprostone, and ○ represents a control group.

Fig. 2 is a graph showing the changes of intraocular pressure with time in respective administration groups. The intraocular pressure is expressed as a change from an initial intraocular pressure. □ represents a Compound B (1-(5-isoquinolinesulfonyl)homopiperazine dihydrochloride) and isopropyl unoprostone combination administration group, ■

represents a single administration group of Compound B, \square represents a single administration group of isopropyl unoprostone, and O represents a control group.

Please replace the paragraph bridging pages 8 and 9 and the first full paragraph on page 9 of the SUBSTITUTED SPECIFICATION filed on October 29, 2008 with the following amended paragraph:

Fig. 3 is a graph showing the changes of intraocular pressure with time in respective administration groups. The intraocular pressure is expressed as a change from an initial intraocular pressure. \square represents a Compound A ((R)-(+)-N-(1H-pyrrolo[2,3-b]pyridine-4-yl)-4-(1-aminoethyl)-benzamide dihydrochloride) and a latanoprost combination administration group, \blacksquare represents a single administration group of Compound A, \square represents a single administration group of latanoprost, and O represents a control group.

Fig. 4 is a graph showing the changes of intraocular pressure with time in respective administration groups. The

intraocular pressure is expressed as a change from an initial intraocular pressure. □ represents a Compound B (1-(5-isoguinolinesulfonyl)homopiperazine dihydrochloride) and a latanoprost combination administration group, ■ represents a single administration group of Compound B, [□] A represents a single administration group of latanoprost, and ○ represents a control group.